Fennec Pharmaceuticals Inc.
PO Box 13628, 68 TW Alexander Drive
Research Triangle Park, NC 27709

 

September 14, 2017

 

Via EDGAR Correspondence

 

Ada D. Sarmento

Office of Healthcare & Insurance

Division of Corporation Finance

Securities and Exchange Commission

100 F. Street, N.E.

Washington D. C. 20549

 

Re:	Acceleration of Effective Date
	Fennec Pharmaceuticals Inc.
	Registration Statement on Form S-1
	File No. 333-219884

 

Dear Ms. Sarmento:

 

Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended (the “Securities Act”), Fennec Pharmaceuticals Inc. (the “Company”) hereby requests that the effective date of the above-referenced Registration Statement (the “Registration Statement”) be accelerated so that the Registration Statement becomes effective under the Securities Act by 4:30 p.m., Eastern Time, on September 18, 2017, or as soon thereafter as practicable.

 

The Company understands that the staff of the Securities and Exchange Commission will consider this request as confirmation by the Company of its awareness of its responsibilities under the federal securities laws as they relate to the offering of the securities covered by the Registration Statement.

 

	Very truly yours,
	FENNEC PHARMACEUTICALS INC.
	By:	/s/ Rostislav Raykov
		Rostislav Raykov
		Chief Executive Officer